{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:57:03Z","timestamp":1776722223957,"version":"3.51.2"},"reference-count":28,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>While transcatheter aortic valve replacement (TAVR) has become a well-established standard of care for patients with symptomatic severe aortic stenosis, the optimal antithrombotic strategy post-TAVR remains a subject of debate, particularly in patients without clear indications for anticoagulation or dual antiplatelet therapy. This study aims to investigate the safety and efficacy of rivaroxaban compared with antiplatelet monotherapy in this specific patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This study is designed as a prospective, multicentre, open-label, randomised controlled trial. A total of 454 patients, who have successfully undergone TAVR and do not have indications for long-term anticoagulation or dual antiplatelet therapy, will be consecutively enrolled from seven centres across China. Participants will be randomly assigned to receive either anticoagulation with rivaroxaban (20\/15\u2009mg) or conventional antiplatelet therapy (aspirin or clopidogrel) for 1\u2009month. Follow-up evaluations are scheduled at 1, 3, 6 and 12 months post-procedure. After the initial 1-month antithrombotic therapy, the regimen may be adjusted by the investigator based on the patient\u2019s clinical and imaging follow-up results. The primary endpoint is a hierarchical composite of cardiovascular death, first occurrence of myocardial infarction or stroke, first occurrence of life-threatening, disabling or major bleeding, and grade 3 or higher hypo-attenuated leaflet thickening and reduced leaflet motion at 12 months post-TAVR. The win ratio method will be employed to analyse the primary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This trial was approved by the Ethics Committee of the Beijing AnZhen Hospital. All relevant results will be disseminated through publications in peer-reviewed journals and presentations at conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR2400087453.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098551","type":"journal-article","created":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T07:30:17Z","timestamp":1755415817000},"page":"e098551","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Rationale and design of SCOPE trial: a prospective, multicentre, open-label, randomised controlled trial to evaluate the overall efficacy and safety of a\n                    <i>s<\/i>\n                    hort-term anticoagulation strategy versus\n                    <i>co<\/i>\n                    nventional single antiplatelet therapy in patients with severe aortic stenosis without indications for anticoagulation or dual antiplatelet therapy\n                    <i>p<\/i>\n                    ost-transcatheter aortic valve r\n                    <i>e<\/i>\n                    placement"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1814-5019","authenticated-orcid":false,"given":"Yunfeng","family":"Yan","sequence":"first","affiliation":[{"name":"Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6973-1333","authenticated-orcid":false,"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5025-0927","authenticated-orcid":false,"given":"Ran","family":"Liu","sequence":"additional","affiliation":[{"name":"Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinmin","family":"Liu","sequence":"additional","affiliation":[{"name":"Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiyang","family":"Luo","sequence":"additional","affiliation":[{"name":"Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhinan","family":"Lu","sequence":"additional","affiliation":[{"name":"Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-2492","authenticated-orcid":false,"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Research and Biometrics Center, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Medical Research and Biometrics Center, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0861-5803","authenticated-orcid":false,"given":"Yi-Da","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cardiology Department, Beijing Hospital, National Center of Gerontology, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tangdu Hospital, Airforce Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Hospital of China Medical University, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Pocock","sequence":"additional","affiliation":[{"name":"EPH, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7868-6132","authenticated-orcid":false,"given":"Guangyuan","family":"Song","sequence":"additional","affiliation":[{"name":"Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SCOPE","family":"Investigators","sequence":"additional","affiliation":[{"name":"Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"2025123106465901000_15.8.e098551.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000923"},{"key":"2025123106465901000_15.8.e098551.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab395"},{"key":"2025123106465901000_15.8.e098551.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509233"},{"key":"2025123106465901000_15.8.e098551.4","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)30757-2","article-title":"Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study","volume":"389","author":"Chakravarty","year":"2017","journal-title":"Lancet"},{"key":"2025123106465901000_15.8.e098551.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.09.022"},{"key":"2025123106465901000_15.8.e098551.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2017.02.005"},{"key":"2025123106465901000_15.8.e098551.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.022"},{"key":"2025123106465901000_15.8.e098551.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.01.045"},{"key":"2025123106465901000_15.8.e098551.9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/ejcts\/ezx244","article-title":"Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"52","author":"Capodanno","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025123106465901000_15.8.e098551.10","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jcin.2022.07.014","article-title":"Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy","volume":"15","author":"Montalescot","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"2025123106465901000_15.8.e098551.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911426"},{"key":"2025123106465901000_15.8.e098551.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.02.051"},{"key":"2025123106465901000_15.8.e098551.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911425"},{"key":"2025123106465901000_15.8.e098551.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017815"},{"key":"2025123106465901000_15.8.e098551.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2022.08.380","article-title":"TCT-325 Pathology of Hypo-Attenuated Leaflet Thickening (HALT) in CoreValve\/Evolut Self-expanding Transcatheter Aortic Valve Bioprostheses","volume":"80","author":"Sato","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025123106465901000_15.8.e098551.16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/heartjnl-2023-322946","article-title":"Impact of leaflet thrombosis on valve haemodynamic status after transcatheter aortic valve replacement","volume":"110","author":"Jang","year":"2023","journal-title":"Heart"},{"key":"2025123106465901000_15.8.e098551.17","doi-asserted-by":"crossref","unstructured":"Steiner-Gager GM , Rogozarski J , Kronberger C , et al . Prediction model for leaflet thrombosis in patients undergoing transcatheter aortic valve implantation: the EFFORT study. Clin Res Cardiol 2024. doi:10.1007\/s00392-024-02486-3","DOI":"10.1007\/s00392-024-02486-3"},{"key":"2025123106465901000_15.8.e098551.18","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jacc.2024.05.064","article-title":"Treatment of Transcatheter Aortic Valve Thrombosis","volume":"84","author":"Adrichem","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025123106465901000_15.8.e098551.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.09.001"},{"key":"2025123106465901000_15.8.e098551.20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa799"},{"key":"2025123106465901000_15.8.e098551.21","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"key":"2025123106465901000_15.8.e098551.22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial","volume":"146","author":"Park","year":"2022","journal-title":"Circulation"},{"key":"2025123106465901000_15.8.e098551.23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr352"},{"key":"2025123106465901000_15.8.e098551.24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa665"},{"key":"2025123106465901000_15.8.e098551.25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4244\/EIJ-D-23-01020","article-title":"Defining high bleeding risk in patients undergoing transcatheter aortic valve implantation: a VARC-HBR consensus document","volume":"20","author":"Garot","year":"2024","journal-title":"EuroIntervention"},{"key":"2025123106465901000_15.8.e098551.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.04.014"},{"key":"2025123106465901000_15.8.e098551.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.08.1045"},{"key":"2025123106465901000_15.8.e098551.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.097"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:48:43Z","timestamp":1767192523000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,16]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2024-098551"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098551","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}